The company noted that more than 40 different robotic endo-surgical instrument types are leveraged by the system, catering to various specialties, including cardiac surgery. Credit: Terelyuk / Shutterstock.

Surgical robotic technology developer SS Innovations has announced its intention to file a de novo classification request for its SSi Mantra 3 surgical robotic system to the US Food and Drug Administration (FDA) in July.

If the agency approves the submission, the system will be authorised for sale in the US market. The company acknowledges that submitting this request does not ensure approval from the FDA.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The application will request clearance for multi-speciality use, including gynaecology, general surgery, thoracic and urology surgery.

Since the systems became commercially available in August 2022, SS Innovations claims to have installed 80 SSi Mantra systems across 75 hospitals.

Since the release of SSi Mantra 3 in June 2024, the company has installed 37 systems that have reportedly been used in more than 750 multi-speciality surgeries. These include 70 cardiac cases, without any reports of device-related injury, complications, or deaths.

According to SS Innovations, the real-world clinical data has been validated by a contract research organisation and provides support for SSi Mantra 3’s capability to safely conduct a broad range of surgeries.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

SS Innovations board chairman and CEO Dr Sudhir Srivastava said:  “We currently have approval to market our SSi Mantra surgical robotic system in six countries and continue to advance our global expansion. We are taking important steps, including the planned de novo application to the FDA, to introduce our empowering, cost-effective surgical robotic technology to the US market.

“In parallel, we are pursuing European Union CE Mark approval for our SSi Mantra surgical robotic system and look forward to our future with great confidence.”

SS Innovations noted that its SSi Mantra Surgical Robotic System features three to five modular robotic arms, an open-faced ergonomic surgeon command centre, and a 3D ultra-high definition [4K] monitor setup.

It also features a virtual real-time image of robotic patient side arm carts, a touch panel for patient information, and the superimposition ability of 3D diagnostic imaging models.

The company noted that more than 40 different robotic endo-surgical instrument types are leveraged by the system, catering to various specialities, inclusive of cardiac surgery. The system has been validated clinically in India for over 100 surgical procedures.

Last November, the company reported carrying out Indonesia’s first robotic cardiac surgery using the SSi Mantra system.

Medical Device Network Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Medical Device Network Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving medical devices advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now